SCTV01E

Phase 3Biologic

SSinocelltech Ltd.

SCTV01E is one of 27 biologic programs targeting COVID-19. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

COVID-19Active, not recruiting

COVID-19Phase 3

Active, not recruiting

Competition

Competitive Landscape

317 competitors in COVID-19

#DrugCompanyPhaseTrials

SCTV01E

SSinocelltech Ltd.

Phase 3

10 2

Stivarga

Bayer

Preclinical

1 3

Aimovig

Amgen

Preclinical

1 4

Aldactone

Pfizer

Preclinical

1 5

Nexavar

Bayer

Preclinical

1 6

Calciferol

Activella

Tricor

1 9

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 10

Benadryl

PParkedale

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

COVID-1910 trials

A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged ≥12 Years Previously Fully Vaccinated With Inactivated COVID-19 Vaccine

Unknown status·SSinocelltech Ltd.·Phase 2·NCT05239806·400 enrolled

A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 Years

Unknown status·SSinocelltech Ltd.·Phase 2·NCT05329051·400 enrolled

A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged ≥18 Years Previously Fully Vaccinated With mRNA COVID-19 Vaccine

Unknown status·SSinocelltech Ltd.·Phase 2·NCT05238441·360 enrolled

Show 7 more trials

A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccines

Unknown status·SSinocelltech Ltd.·Phase 2·NCT05933512·600 enrolled

A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine SCTV01E-1 in Population Aged Above 18 Years

Unknown status·SSinocelltech Ltd.·Phase 2·NCT05522829·400 enrolled

A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines

Unknown status·SSinocelltech Ltd.·Phase 3·NCT05323461·1,800 enrolled

A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 Years

Unknown status·SSinocelltech Ltd.·Phase 2·NCT05345873·300 enrolled

A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in Population Aged ≥12 Years

Withdrawn·SSinocelltech Ltd.·Phase 2·NCT05308602

A Study to Evaluate the Efficacy and Safety of SCTV01E (a COVID-19 Vaccine) in Population Aged ≥18 Years

Active, not recruiting·SSinocelltech Ltd.·Phase 3·NCT05308576·10,000 enrolled

A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 Vaccine

Completed·SSinocelltech Ltd.·Phase 2·NCT05652543·518 enrolled

Efficacy and Safety1 trial

A Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E in Healthy People

Unknown status·SSinocelltech Ltd.·Phase 3·NCT05683561·6,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for SCTV01E. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SCTV01E compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SCTV01E. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sinocelltech Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: SSinocelltech Ltd.

SCTV01E

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

COVID-1910 trials

Efficacy and Safety1 trial

References

Drug Info

Quick Facts

Related News